Monobutyl phthalate


CAS No. : 131-70-4

131-70-4
Price and Availability of CAS No. : 131-70-4
Size Price Stock
5g $56 In-stock
10g $93 In-stock
25g $181 In-stock
50 g Get quote
100 g Get quote
We match the lowest price on market.

We offer a substantial discount on larger orders, please inquire via [email protected]

or Fax: (86)21-58955996

Inquiry for price and availability only. Please place your order via our email or fax.

Cat. No. : HY-N7143
M.Wt: 222.24
Formula: C12H14O4
Purity: >98 %
Solubility: DMSO : 100 mg/mL (ultrasonic)
Introduction of 131-70-4 :

Monobutyl phthalate is an orally active metabolite of Di-n-butyl phthalate (HY-Y0304) and an embryotoxic agent. Monobutyl phthalate regulates mesodermal lineage gene expression, inhibits uterine decidualization, reduces fetal testosterone levels without directly binding to the androgen receptor, and induces teratogenic effects during organogenesis. Monobutyl phthalate induces testicular oxidative stress and sperm abnormalities. Monobutyl phthalate can be used in studies of developmental toxicity and male reproductive toxicity[1][2][3][4]. In Vitro:Monobutyl phthalate (0.045-4.5 mM; from suspension culture to day 10 of differentiation) inhibits cardiomyocyte differentiation of mouse D3 ESCs, with an ID50 of 1.35 mM[1].
Monobutyl phthalate (1.35 mM) only causes a slight decrease in the viability of cells derived from mouse D3 ESCs, with a remaining viability of over 90% relative to the control group[1].
Monobutyl phthalate (1.35 mM) upregulates gene sets associated with pluripotency, proliferation, and non-mesodermal differentiation in differentiating mouse D3 ESC embryoid bodies, while specifically downregulating the early cardiomyocyte differentiation gene set 'VAN DARTEL HEARTDIFF 24H', indicating inhibition of mesodermal cardiomyocyte differentiation at the transcriptional level[1].
Monobutyl phthalate (96 h) induces cytotoxicity and inhibits chondrogenic differentiation in limb bud cells of Wistar rat embryos on gestation day 12.5 in a concentration-dependent manner, with an IC50 of 1.38 mM for cytotoxicity and an IC50 of 0.64 mM for differentiation inhibition[3]. In Vivo:Monobutyl phthalate (250-1000 mg/kg; p.o.; daily; days 0-8 of pregnancy) administered during early pregnancy (days 0-8) at 1000 mg/kg induces pre- and postimplantation embryonic loss, and at 500 mg/kg and higher reduces fetal weight and maternal weight gain/food consumption[2].
Monobutyl phthalate (250-1000 mg/kg; p.o.; daily; days 0-8 of pseudopregnancy) at 1000 mg/kg suppresses uterine decidualization in pseudopregnant rats[2].
Monobutyl phthalate (500-750 mg/kg; p.o.; daily for 3 consecutive days; on either days 7-9, 10-12, or 13-15 of pregnancy) exerts phase-specific teratogenic effects in rats, with susceptibility windows on days 7-9 and 13-15 of pregnancy, inducing distinct patterns of external and skeletal malformations[2].
Monobutyl phthalate (25-200 mg/kg; p.o.; once daily; 14 days) induces dose-dependent testicular toxicity in male Balb/c mice, with 200 mg/kg causing severe seminiferous tubule degeneration, 27.3% elevated ROS, 28.3% elevated MDA, and significant down-regulation of Sox9 and Dazl mRNA[4].

Your information is safe with us.